Methyl chloroformate → 2-[4-(2-{(1S,2R)-2-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]cyclopropyl}ethoxy)-2-fluorophenyl]-acetohydrazide

Participants

Reaction Conditions

Reaction Steps

A solution of [4-(2-{(1S,2R)-2-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]cyclopropyl}ethoxy)-2-fluorophenyl]acetic acid (500 mg, 1.152 mmol) in 5 mL of THF cooled to −10° C. and TEA (0.177 mL, 1.268 mmol) was added. Methyl chloroformate (0.098 mL, 1.268 mmol) was added and the mixture stirred for 30 minutes at −10° C. The mixture was filtered and the filtercake washed with 10 mL THF. The filtrate was collected and concentrated under reduced pressure. The residue (265 mg, 0.539 mmol) was dissolved in 1 mL of DMF and hydrazine monohydrate (0.052 mL, 1.077 mmol) added. The mixture was stirred overnight at room temperature. The mixture was diluted with ethyl acetate (3 mL) and washed with water (2 mL) and brine (2 mL). The organics fractions were combined, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified using preparative TLC (1000 μM, silica gel) developing with 5% methanol in DCM. The band containing the product was collected and the silica washed with 10% methanol in DCM to elute the product. The solution was concentrated under reduced pressure to afford the title compound. HPLC/MS; 1.22 min(2 minute run), 448 (M+H)+.

Provenance & Evidence